Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.83 +0.06 (+0.23%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
How To Earn $500 A Month From Pfizer Stock
New York-based Pfizer currently has a dividend yield of 5.96% — a quarterly dividend of 42 cents a share ($1.68 a year). 
Via Benzinga
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
From Pfizer Inc.
Via Business Wire
Ginkgo Bioworks Stock: Bull vs. Bear
This innovative biotechnology company hopes to turn things around. 
Via The Motley Fool
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Pfizer's dividend yield is rising as the stock price is falling. 
Via The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
1 No-Brainer Dividend Stock Yielding More Than 5% to Buy and Hold Forever
Going against the grain here looks like a great idea. 
Via The Motley Fool
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
Exposures COVID-19
Moderna Pops After Confirming The U.S. Government Could Back Its Bird Flu Vaccine
The company expects to have data soon from its Phase 1 and Phase 2 study of a bird flu vaccine. 
Via Investor's Business Daily
Beat the Dow Jones With This Cash-Gushing Dividend Stock
With one decade of doubling the Dow Jones' total return under its belt, Zoetis looks ready to deliver another 10 years of outperformance. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Steady Gains, Solid Yields: 7 Low-Beta Stocks Paying 5%+ Dividends
These are the low-beta dividend stocks to buy, as they represent companies with strong fundamentals and robust cash flow visibility. 
Via InvestorPlace
3 Dividend Stocks to Double Up on Right Now
The stories for these great dividend stocks are better than many might think. 
Via The Motley Fool
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history. 
Via Benzinga
Topics Economy Retirement
Exposures Economy Pension
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
Both businesses have road maps for the future, but one is better. 
Via The Motley Fool
7 Must-Own Stocks to Hold for the Second Half of 2024
Explore 7 must-own stocks for the second half of the year set to drive substantial yields across multiple innovative sectors. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy. 
Via InvestorPlace
Exposures Product Safety
If You Can Only Buy One Value Stock in May, It Better Be One of These 3 Names
Although the ideas may be less appreciated, these value stocks to buy can deliver surprisingly positive results for contrarians. 
Via InvestorPlace
Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge. 
Via Benzinga
Exposures Product Safety
Revenge of the Apes: 3 Reddit WallStreetBets Stocks That Could Pop Next
The retail trading army could cause potential breakouts in these three WallStreetBets stocks that are being discussed more and more. 
Via InvestorPlace
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,
Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter financial results. 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
2 Beaten-Down Dividend Stocks Near 52-Week Lows. Should You Buy the Dips?
The major market indexes keep hitting new highs, but these stocks haven't participated in the bull run. 
Via The Motley Fool
Dividend Deals: 3 Overlooked Stocks Offering Incredible Value
Build a portfolio that steadily generates passive income for you. Here are three overlooked dividend stocks to consider. 
Via InvestorPlace
Got $500? 3 Pharma Stocks to Buy and Hold Forever
These players might even beat the market when the conditions are right. 
Via The Motley Fool
How Much Will Pfizer Pay Out in Dividends This Year?
As one of the world's largest drugmakers, Pfizer generates lots of cash it can share with investors. 
Via The Motley Fool
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Why Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely? 
Via The Motley Fool
3 Stocks That Can Help You to Get Richer in 2025 and Beyond
These are three solid contenders for your portfolio. 
Via The Motley Fool
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.